BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9349315)

  • 1. The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas.
    Crippa F; Gavazzi C; Bozzetti F; Chiesa C; Pascali C; Bogni A; De Sanctis V; Decise D; Schiavini M; Cucchetti G; Bombardieri E
    Tumori; 1997; 83(4):748-52. PubMed ID: 9349315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
    Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
    J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases.
    Revheim ME; Haugvik SP; Johnsrud K; Mathisen Ø; Fjeld JG; Skretting A
    Acta Radiol; 2015 Apr; 56(4):397-403. PubMed ID: 24682406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver.
    Kurtaran A; Becherer A; Pfeffel F; Müller C; Traub T; Schmaljohann J; Kaserer K; Raderer M; Schima W; Dudczak R; Kletter K; Virgolini I
    Liver; 2000 Dec; 20(6):487-90. PubMed ID: 11169064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
    Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
    Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
    Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.
    Lindholm P; Minn H; Leskinen-Kallio S; Bergman J; Ruotsalainen U; Joensuu H
    J Nucl Med; 1993 Jan; 34(1):1-6. PubMed ID: 8418248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
    Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
    Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
    J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
    Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
    Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).
    Fernandez FG; Drebin JA; Linehan DC; Dehdashti F; Siegel BA; Strasberg SM
    Ann Surg; 2004 Sep; 240(3):438-47; discussion 447-50. PubMed ID: 15319715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease.
    Denecke T; Steffen I; Hildebrandt B; Rühl R; Streitparth F; Lehmkuhl L; Langrehr J; Ricke J; Amthauer H; Hänninen EL
    Acta Radiol; 2007 Oct; 48(8):821-30. PubMed ID: 17924212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET).
    Mantaka P; Strauss AD; Strauss LG; Moehler M; Goldschmidt H; Oberdorfer F; Kontaxakis G; Van Kaick G
    Anticancer Res; 1999; 19(5C):4443-50. PubMed ID: 10650790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.
    Truant S; Huglo D; Hebbar M; Ernst O; Steinling M; Pruvot FR
    Br J Surg; 2005 Mar; 92(3):362-9. PubMed ID: 15672427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.
    Lee JW; Kim SK; Lee SM; Moon SH; Kim TS
    Mol Imaging Biol; 2011 Jun; 13(3):565-572. PubMed ID: 20683670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.
    Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D
    Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation.
    Grut H; Revheim ME; Line PD; Dueland S
    Nucl Med Commun; 2018 Jul; 39(7):621-627. PubMed ID: 29683930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.